Treatment of muscle weakness in neuromuscular disorders

Abstract : Weakness is one of the predominant clinical manifestations of neuromuscular disorders (NMDs), which strongly influences daily life, prognosis, and outcome of affected patients. One of the major therapeutic goals in NMD-patients is to completely resolve muscle weakness. Various treatment options are available and include physical therapy, electrotherapy, diet, drugs, avoidance or withdrawal of muscle-toxic and weakness-inducing agents, detoxification, stem-cell-therapy, plasma-exchange, respiratory therapy, or surgery. Most accessible to treatment is weakness from immune-mediated neuropathies, immune-mediated transmission-disorders, and idiopathic immune myopathies. Areas covered: This manuscript aims to summarize and discuss recent findings and future perspectives concerning the treatment of muscle weakness in NMDs. Data were obtained by a literature search in databases such as PubMed and Current-Contents. Expert commentary: Weakness is most easily treatable in acquired NMDs and in hereditary myopathies and neuropathies beneficial treatment options are also available. Research needs to be encouraged and intensified to further expand the spectrum of treatment options for weakness.
Type de document :
Article dans une revue
Expert Review of Neurotherapeutics, Expert Reviews (formerly Future Drugs), 2016, 16 (12), pp.1383-1395. 〈10.1080/14737175.2016.1206471 〉
Liste complète des métadonnées

https://hal-riip.archives-ouvertes.fr/pasteur-01436296
Contributeur : Institut Pasteur Tunis <>
Soumis le : lundi 16 janvier 2017 - 12:43:11
Dernière modification le : lundi 5 février 2018 - 15:22:13

Identifiants

Collections

Citation

Josef Finsterer, Sinda Zarrouk-Mahjoub. Treatment of muscle weakness in neuromuscular disorders. Expert Review of Neurotherapeutics, Expert Reviews (formerly Future Drugs), 2016, 16 (12), pp.1383-1395. 〈10.1080/14737175.2016.1206471 〉. 〈pasteur-01436296〉

Partager

Métriques

Consultations de la notice

26